Budesonide Alternatives Compared
Budesonide | Humira (adalimumab) | Entyvio (vedolizumab) |
|
---|
Budesonide | Humira (adalimumab) | Entyvio (vedolizumab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Inflammatory Bowel Disease, Crohn's Disease, Autoimmune Hepatitis, Asthma, Eosinophilic Esophagitis, Crohn's Disease - Active, Asthma - Maintenance, Crohn's Disease - Maintenance... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Related suggestions Ulcerative Colitis
Crohn's Disease
Crohn's Disease, Maintenance
|
|||||||||||||||||||||||
More about Budesonide | More about Humira (adalimumab) | More about Entyvio (vedolizumab) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Budesonide has an average rating of 6.8 out of 10 from a total of 177 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 18% reported a negative effect. |
Humira has an average rating of 6.4 out of 10 from a total of 703 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 30% reported a negative effect. |
Entyvio has an average rating of 6.3 out of 10 from a total of 166 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 28% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Budesonide side effects |
View all Humira side effects |
View all Entyvio side effects |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Budesonide prices |
View all Humira prices |
View all Entyvio prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Entocort EC, Eohilia, Pulmicort Flexhaler, Pulmicort Respules, Tarpeyo, Uceris | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | Other vedolizumab brands include: Entyvio Pen | ||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
2.8 hours |
480 hours |
600 hours |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 566 drugs are known to interact with Budesonide:
|
A total of 555 drugs are known to interact with Humira:
|
A total of 169 drugs are known to interact with Entyvio:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
October 02, 2001 |
December 31, 2002 |
May 20, 2014 |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
|||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Tarpeyo
Tarpeyo (budesonide) is an oral, delayed-release, corticosteroid capsule that may be used to reduce ...
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Filspari
Filspari is used for primary immunoglobulin A nephropathy (IgAN), to slow kidney function decline ...
Omvoh
Omvoh is used to treat moderate to severe ulcerative colitis or Crohn's disease in adults. This ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Humira
Humira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...
Xolair
Xolair injection (omalizumab) is used to help improve allergic asthma, nasal polyps, and chronic ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.